Node negative breast cancer: The prognostic value of DNA ploidy for long-term survival
Article first published online: 6 DEC 2005
Copyright © 1991 British Journal of Surgery Society Ltd.
British Journal of Surgery
Volume 78, Issue 7, pages 844–848, July 1991
How to Cite
Yuan, J., Hennessy, C., Corbett, I. P., Dykin, R., Givan, A. L., Shenton, B. K., Henry, J. A., Wright, C. and Lennard, T. W. J. (1991), Node negative breast cancer: The prognostic value of DNA ploidy for long-term survival. Br J Surg, 78: 844–848. doi: 10.1002/bjs.1800780724
- Issue published online: 6 DEC 2005
- Article first published online: 6 DEC 2005
- Manuscript Accepted: 15 FEB 1991
- North of England Cancer Research Campaign
- State Education Commission, People's Republic of China
The DNA content of breast tumours from 170 patients who presented between 1978 and 1980 was measured by flow cytometry. The relationship between tumour ploidy and disease outcome was assessed and its association with other prognostic factors evaluated. Compared with those with diploid tumours, patients with aneuploid tumours had significantly earlier relapse and shorter survival (P<0·0001). Tumour ploidy was strongly related to grade (P<0·001), but there was no significant association between DNA ploidy and c-erb-B-2 expression, lymph node status or tumour size. In lymph node negative and c-erb-B-2 negative patients, aneuploid tumours were associated with a poorer prognosis (P<0·001) than diploid tumours. Multivariate analysis showed that tumour ploidy gave independent information on disease free and overall survival. Tumour ploidy may be used as an independent prognostic variable in patients with breast cancer and it may be helpful in defining patients within the node negative or c-erb-B-2 negative groups likely to have a poor outcome who might benefit from adjuvant treatment.